Drug Farm's Rare Disease Drug Gains Key FDA Program Acceptance

ALBANY, N.Y. – March 05, 2026 – In a significant development for patients with the ultra-rare ROSAH syndrome, biotechnology company Drug Farm announced its investigational therapy, DF-003, has been accepted into the U.S. Food and Drug Administration's (FDA) new Rare Disease Evidence Principles Process (RDEP). This acceptance marks a critical step forward, potentially accelerating the development of the first-ever treatment for a debilitating genetic disorder that currently has none.

For the small community of individuals affected by ROSAH syndrome, a condition characterized by progressive vision loss and systemic inflammation, this news represents a tangible glimmer of hope. The RDEP initiative is specifically designed to streamline the path to approval for therapies targeting diseases with extremely small patient populations, offering a collaborative framework between regulators and drug developers to overcome the unique challenges of rare disease research.

A New Regulatory Pathway for Ultra-Rare Diseases

The FDA's Rare Disease Evidence Principles Process is a novel and pivotal initiative aimed at transforming the drug development landscape for the rarest of conditions. Unlike the broader Orphan Drug Act, which covers diseases affecting up to 200,000 people in the U.S., the RDEP is tailored for ultra-rare disorders, often impacting fewer than 1,000 patients nationwide.

This program acknowledges that traditional, large-scale clinical trials are often impossible for such small populations. Instead, RDEP allows for a more flexible approach to demonstrating a drug's safety and effectiveness. Under this framework, a single, well-controlled study, potentially with a small number of participants, can be considered sufficient for approval when supported by a robust body of confirmatory evidence. This can include strong mechanistic data, results from preclinical models, and natural history studies that track the disease's progression in untreated patients.

Acceptance into the RDEP program is highly selective. It is reserved for therapies targeting serious or life-threatening diseases caused by a known genetic defect, where patients face rapid decline and have no other treatment options. By engaging sponsors like Drug Farm in early and structured dialogue, the FDA aims to reduce regulatory uncertainty, encourage investment, and ultimately hasten the delivery of vital medicines to patients who cannot afford to wait.

The Devastating Impact of ROSAH Syndrome

ROSAH syndrome—an acronym for retinal dystrophy, optic nerve edema, splenomegaly, anhidrosis, and headache—is a severe, autosomal dominant autoinflammatory disease. It is caused by a specific type of genetic defect: a "gain-of-function" mutation in the ALPK1 gene. This mutation essentially puts a key part of the body's innate immune system into a state of constant overdrive.

The consequences for patients, who often begin showing symptoms in childhood or early adulthood, are profound. The most prominent feature is progressive damage to the eyes, including retinal degeneration and swelling of the optic nerve, which can lead to irreversible vision loss and blindness. Beyond the ocular symptoms, patients suffer from systemic inflammation, evidenced by elevated inflammatory markers, an enlarged spleen, and chronic headaches.

The genetic basis of ROSAH syndrome is clear, but the path to a treatment has been non-existent. With no approved therapies available to modify the disease's course, management has been limited to addressing individual symptoms. This leaves patients and their families to confront the relentless progression of the disorder, facing a future of increasing disability with no effective medical recourse. The lack of treatment options defines ROSAH syndrome as a condition with a critical and urgent unmet medical need.

A Targeted Approach with a First-in-Class Inhibitor

Drug Farm's DF-003 is engineered to address the root cause of ROSAH syndrome. As a proprietary, first-in-class small molecule, it is designed to directly inhibit the overactive ALPK1 enzyme. By blocking the activity of this enzyme, the drug aims to quell the runaway inflammatory cascade that drives the disease's pathology, potentially halting or reversing its devastating effects. The scientific foundation for this approach is strong, with preclinical data published in the peer-reviewed journal Nature Communications.

The clinical development program for DF-003 is already underway. The company has successfully completed a Phase 1 trial (NCT05997641) in healthy volunteers to establish its safety profile. Now, Drug Farm is actively enrolling ROSAH syndrome patients into a Phase 1b clinical trial (NCT06395285), a crucial step to evaluate the drug's safety and preliminary efficacy in the very population it is intended to help.

"Acceptance into the Rare Disease Evidence Principles Process provides an important opportunity for early collaboration with the FDA as we advance DF-003 for patients with ROSAH syndrome," said Henri Lichenstein, Ph.D., Chief Executive Officer at Drug Farm, in a statement. "Given the rarity of this disease and the lack of approved treatments, we believe engagement through RDEP will help inform efficient development strategies and accelerate progress toward potential therapies for patients."

AI-Powered Discovery and a Broader Horizon

The discovery of DF-003 was not a matter of chance but the result of a sophisticated and modern approach to drug development. Drug Farm utilized its unique IDInVivo platform, a proprietary system that combines advanced genetics with artificial intelligence. This platform enables the company's scientists to identify and validate novel drug targets directly within living animal models that have intact immune systems, providing a more accurate reflection of how a drug might behave in humans.

The success of the IDInVivo platform in identifying a viable candidate for a complex rare disease like ROSAH syndrome serves as a powerful validation of this technology. It represents a shift towards a more efficient and targeted era of drug discovery, where AI and genetic insights can unlock solutions for previously intractable medical problems.

While the immediate focus is on ROSAH syndrome, the potential applications for ALPK1 inhibition may be much broader. Drug Farm has noted that DF-003 has shown promise in preclinical models for more common conditions, including certain types of heart and kidney disease where ALPK1-mediated inflammation is believed to play a role. This suggests that the work being done for a small group of rare disease patients could eventually have a far-reaching impact on medicine, demonstrating how research into rare conditions can drive innovation for all. The collaborative pathway forward with the FDA will be crucial in navigating the clinical and regulatory journey for this promising new therapy.